Open an account

Cytosorbents

CTSO · NASDAQ

$5.32+$0.36 (+7.26%)TodayMarket closed ·
Prev close $4.96

About CTSO

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. The company is headquartered in Princeton, New Jersey and currently employs 129 full-time employees. The company went IPO on 2005-06-17. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.

Employees
129
Headquarters
Princeton, New Jersey
Listed
Jun 17, 2005
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
cytosorbents.com

CTSO key statistics

Market cap
16.76M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
57.20K
Volume
79.31K
Open price
$4.88
High today
$5.35
Low today
$4.53
52 Week high
$18.00
52 Week low
$2.84

Cytosorbents (CTSO) at a glance

Cytosorbents (CTSO) last traded at $5.32, with a market cap of 16.76M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.53 and $5.35. The current price is 17.3% above the day's low and 0.6% below its high.

Volume so far is 79.31K shares, above the average of 57.20K shares a day.

Over the past year Cytosorbents has ranged from $2.84 to $18.00, and now sits 16% of the way up that range.

Cytosorbents met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$1.40 per share against an estimate of -$0.918.

The average analyst price target is $48.45, 810.7% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 4 analystsAvg $48.45
Low
$15.15
Now
$5.32
High
$84.00

CTSO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 89.6% on average.

  1. Q3 FY24: reported -$0.04 per share against an estimate of -$0.0646
  2. Q4 FY24: reported -$0.14 per share against an estimate of -$0.0646
  3. Q1 FY25: reported -$0.02 per share against an estimate of -$0.0714
  4. Q2 FY25: reported $0.03 per share against an estimate of -$0.051
  5. Q3 FY25: reported -$0.05 per share against an estimate of -$0.0476
  6. Q4 FY25: reported -$0.09 per share against an estimate of -$0.051
  7. Q1 FY26: reported -$1.60 per share against an estimate of -$1.12
  8. Q2 FY26: reported -$1.40 per share against an estimate of -$0.918

CTSO news

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Press releasePRNewswire

    CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care

  • Press releasePRNewswire

    CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement

  • Press releasePRNewswire

    CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference

  • Press releasePRNewswire

    CytoSorbents Announces Reverse Stock Split

  • Press releasePRNewswire

    CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releasePRNewswire

    CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

Similar companies

Companies in the same industry as Cytosorbents

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.